Dara- Revlimid, Ixazomib & Dex: A Promising Option for Some Myeloma Patients| Andrew Yee, MD #IMS25

Dara- Revlimid, Ixazomib & Dex: A Promising Option for Some Myeloma Patients| Andrew Yee, MD #IMS25
Updates from IMS on CAR-T & Bispecifics in Myeloma | Rahul Banerjee, MD | #IMS2025
Ide-cel Efficacy in Myeloma Correlates with Endogenous Immune Profiles | Bruno Paiva, PhD | #IMS25
What Drives Myeloma Treatment Decisions After Relapse? | Paola Anchondo | #IMS2025
Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma
MGIP: The Earliest Warning Sign of Myeloma Evolution | Sungjae Kim, PhD | #IMS2025
CELMoDs: Boosting T-Cell Therapies with Iberdomide & Mezigdomide | Joshua Richter, MD| #IMS2025
Ferritin & ALC Predict PFS in Myeloma Bispecific Antibody Therapy | Tarek Mouhieddine, MD #IMS25
Blood Test Reveals Myeloma Genetics Using Cell-Free DNA | Dory Abelman, PhdD(c) #IMS25
How MRD Status Is Being Used to Guide Myeloma Treatment Decisions | Ben Derman MD #IMS25
Lymphocyte Count Used to Predict Delayed Neurotoxicity in Myeloma CAR-T | Hitomi Hosoya MD #ims25
Shared Decision-Making Matters When Choosing Myeloma Treatment | Martine Elias,Myeloma Canada #IMS25
MRD Relapse vs Biochemical Relapse -Restarting Myeloma Therapy | Fredrik Schjesvold, MD, PhD #IMS25